Core Viewpoint - The company, Gilead Sciences-B (01672), plans to issue 69.256 million shares, representing approximately 6.98% of its total issued shares as of the announcement date, to raise funds for clinical trials and operational needs [1] Group 1: Share Placement Details - The placement price is set at HKD 12.18 per share, which is about a 4.0% discount compared to the closing price of HKD 12.69 on February 2 [1] - The total expected proceeds from the placement are approximately HKD 843.5 million, with net proceeds estimated at around HKD 835.3 million [1] Group 2: Use of Proceeds - Approximately 90% of the net proceeds is intended for the preparation, groundwork, and initiation of global Phase III clinical trials for the oral GLP-1 receptor agonist ASC30, aimed at treating obesity [1] - The remaining 10% of the net proceeds is suggested for working capital and other general corporate purposes [1]
歌礼制药-B(01672)拟折让约4%配售6925.6万股 净筹约8.353亿港元